Latest NCCN Guidelines on AML Treatment
Current NCCN guidelines stress the importance of treating Acute Myeloid Leukemia (AML) at experienced centers with proper infrastructure.
Treatment decisions are based on eligibility for intensive vs nonintensive therapy and specific genetic mutations like FLT3, IDH1, and TP53.
- Patient evaluation at specialized centers with comprehensive support services.
- Initial treatment decision based on intensive chemotherapy eligibility.
- Genetic testing results guide treatment selection.
Genetic testing results, available within 1 to 2 weeks, guide treatment selection by identifying specific mutations that respond to targeted therapies.
Author's summary: NCCN guidelines emphasize treating AML at experienced centers.